Dataset Information

Vitamin D Receptor Activation and Photodynamic Priming Enables Durable Low-dose Chemotherapy.

ABSTRACT: Patients with cancer often confront the decision of whether to continue high-dose chemotherapy at the expense of cumulative toxicities. Reducing the dose of chemotherapy regimens while preserving efficacy is sorely needed to preserve the performance status of these vulnerable patients, yet has not been prioritized. Here, we introduce a dual pronged approach to modulate the microenvironment of desmoplastic pancreatic tumors and enable significant dose deescalation of the FDA-approved chemotherapeutic nanoliposomal irinotecan (nal-IRI) without compromising tumor control. We demonstrate that light-based photodynamic priming (PDP) coupled with vitamin D3 receptor (VDR) activation within fibroblasts increases intratumoral nal-IRI accumulation and suppresses protumorigenic CXCL12/CXCR7 crosstalk. Combined photodynamic and biochemical modulation of the tumor microenvironment enables a 75% dose reduction of nal-IRI while maintaining treatment efficacy, resulting in improved tolerability. Modifying the disease landscape to increase the susceptibility of cancer, via preferentially modulating fibroblasts, represents a promising and relatively underexplored strategy to enable dose deescalation. The approach presented here, using a combination of three clinically available therapies with nonoverlapping toxicities, can be rapidly translated with minimal modification to treatment workflow, and challenges the notion that significant improvements in chemotherapy efficacy can only be achieved at the expense of increased toxicity.

SUBMITTER: Anbil S

PROVIDER: S-EPMC7272264 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Vitamin D Receptor Activation and Photodynamic Priming Enables Durable Low-dose Chemotherapy.

Anbil Sriram S Pigula Michael M Huang Huang-Chiao HC Mallidi Srivalleesha S Broekgaarden Mans M Baglo Yan Y De Silva Pushpamali P Simeone Diane M DM Mino-Kenudson Mari M Maytin Edward V EV Rizvi Imran I Hasan Tayyaba T

Molecular cancer therapeutics 20200327 6

Patients with cancer often confront the decision of whether to continue high-dose chemotherapy at the expense of cumulative toxicities. Reducing the dose of chemotherapy regimens while preserving efficacy is sorely needed to preserve the performance status of these vulnerable patients, yet has not been prioritized. Here, we introduce a dual pronged approach to modulate the microenvironment of desmoplastic pancreatic tumors and enable significant dose deescalation of the FDA-approved chemotherape ...[more]

PMID: 32220968

Similar Datasets

Project description:The aim of this study was to examine whether decitabine priming prior to low-dose chemotherapeutic regimens could improve outcomes in patients with myelodysplastic syndromes-refractory anemia with excess of blasts (MDS-RAEB).The current retrospective analysis included all MDS-RAEB patients receiving idarubicin/cytarabine (IA) or aclacinomycin/cytarabine (AA), with or without decitabine priming during a period from February 2010 to May 2015. Treatment response and toxicity were compared between patients receiving decitabine priming and those who did not. A panel of 6 MDS-related genes was examined using bone marrow specimens.A total of 81 patients were included in the analysis: 40 received decitabine priming prior to chemotherapy (decitabine priming group). The median follow-up was 10.9 months (IQR: 6.2-21.9). The rate of overall response (OR) and complete remission (CR) was significantly higher in the decitabine priming group than in the chemotherapy group (OR: 75.0 vs. 51.2%, p?=?0.027; CR: 55.0 vs. 29.3%, p?=?0.019). Overall survival (OS) did not differ significantly between the two groups (19.5 vs. 14.7 months, p?=?0.082). In a subgroup analysis that included only patients at <?60 years of age, the CR rate in the decitabine priming group was significantly higher than in the chemotherapy group (65.5 vs. 31.0%, p?=?0.009). Survival benefit of decitabine priming was apparent in patients at <?60 years of age (22.4 months with 95% CI of 6.7-38.1 vs. 14.7 months with 95% CI of 11.4-18.0 months in the chemotherapy group, p?=?0.028), patients with intermediate and unfavorable karyotypes (22.4 months with 95% CI of 15.1-29.7 vs. 11.9 months with 95% CI of 4.0-19.8 months in the chemotherapy group, p?=?0.042), and patients with mutated splicing factor genes (35.3 months with 95% CI of 21.4-49.2 vs. 17.8 months with 95% CI of 13.8-21.8 months in the chemotherapy group, p?=?0.039). Grade 3-4 hematological and non-hematological toxicities were not significantly different between the two groups.Decitabine priming prior to low-dose chemotherapy could improve treatment responses in patients with MDS-RAEB.

Dataset Information

Vitamin D Receptor Activation and Photodynamic Priming Enables Durable Low-dose Chemotherapy.

Publications

Vitamin D Receptor Activation and Photodynamic Priming Enables Durable Low-dose Chemotherapy.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets